Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic naïve: 6-month results from a real-world, international, pro...

por Alten, Rieke, Nüßlein, Hubert G, Mariette, Xavier, Galeazzi, Mauro, Lorenz, Hanns-Martin, Cantagrel, Alain, Chartier, Melanie, Poncet, Coralie, Rauch, Christiane, Le Bars, Manuela
Publicado 2017

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study

por Alten, Rieke, Mariette, Xavier, Lorenz, Hanns-Martin, Galeazzi, Mauro, Cantagrel, Alain, Nüßlein, Hubert G, Chartier, Melanie, Elbez, Yedid, Rauch, Christiane, Le Bars, Manuela
Publicado 2017

Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

por Nüßlein, Hubert G., Alten, Rieke, Galeazzi, Mauro, Lorenz, Hanns-Martin, Nurmohamed, Michael T., Bensen, William G., Burmester, Gerd R., Peter, Hans-Hartmut, Pavelka, Karel, Chartier, Melanie, Poncet, Coralie, Rauch, Christiane, Le Bars, Manuela
Publicado 2015

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective...

por Nüßlein, Hubert G, Alten, Rieke, Galeazzi, Mauro, Lorenz, Hanns-Martin, Boumpas, Dimitrios, Nurmohamed, Michael T, Bensen, William G, Burmester, Gerd R, Peter, Hans-Hartmut, Rainer, Franz, Pavelka, Karel, Chartier, Melanie, Poncet, Coralie, Rauch, Christiane, Bars, Manuela Le
Publicado 2014